Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Shares Outstanding readings, the most recent being $46.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding fell 36.74% to $46.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $46.1 million, a 36.74% decrease, with the full-year FY2025 number at $76.3 million, up 5.21% from a year prior.
  • Shares Outstanding hit $12.8 million in Q1 2026 for Kiniksa Pharmaceuticals International, roughly flat from $12.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $74.0 million in Q2 2025 to a low of $1.0 in Q2 2024.
  • Median Shares Outstanding over the past 5 years was $69.8 million (2023), compared with a mean of $56.4 million.
  • Biggest five-year swings in Shares Outstanding: crashed 100.0% in 2024 and later soared 7403236200.0% in 2025.
  • Kiniksa Pharmaceuticals International's Shares Outstanding stood at $69.7 million in 2022, then grew by 1.09% to $70.5 million in 2023, then grew by 2.92% to $72.5 million in 2024, then increased by 5.21% to $76.3 million in 2025, then plummeted by 39.64% to $46.1 million in 2026.
  • The last three reported values for Shares Outstanding were $46.1 million (Q1 2026), $76.3 million (Q4 2025), and $44.8 million (Q3 2025) per Business Quant data.